GlobeNewswire·Oct 22, 2026, 8:30 AM ET

Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea

DRTS DRTSW

Alpha Tau Medical Ltd. signed an MOU with Samsung Medical Center (SMC) in Seoul for a potential first clinical trial of Alpha DaRT in South Korea, subject to regulatory & ethics approvals.
The trial targets pancreatic cancer patients at SMC, which ranks fifth globally & first in Korea for oncology.
In Korea, only one in five pancreatic cancer patients undergo surgery, & the disease's death rate rose over 6% in 2025, marking the steepest increase among major cancers.
Pancreatic cancer is Korea's fourth leading cause of cancer death, with a 2023 diagnosis count of 9,748 & a five-year relative survival rate of 17.0%, the lowest of any cancer in the country.
Fewer than one in six Korean patients are diagnosed while the cancer is confined to the pancreas, while more than 40% are diagnosed after it has spread to distant organs.
SMC's Pancreatobiliary Cancer Center has performed over 4,000 pancreatectomies for pancreatic cancer between 2008 & 2025.
Alpha DaRT is an alpha-radiation therapy using radium-224 sources to deliver high-energy alpha particles that destroy tumors while sparing surrounding healthy tissue.
Alpha Tau aims to potentially expand its pancreatic cancer program to six countries across North America, Europe, the Middle East, & Asia following this collaboration.
Alpha DaRT is currently approved commercially only in Japan for unresectable locally advanced or recurrent head & neck cancer, with no other commercial approvals outside of approved trials.
SMC was ranked fifth in the world & first in Korea in oncology in Newsweek's World's Best Specialized Hospitals 2027.